SORRY DR. HANNAH ROSENBLUM, C0VID-19 SAFETY MONITORING IS NOT THE MOST ROBUST IN THE U.S., or THE WORLD

This is pretty striking data suggesting that COVID jabs are harming children.  https://t.co/mQSIF02BcR

— Stephanie Seneff (@stephanieseneff) July 9, 2022

Well, Dr. Moybeen Syed is angry.  Why did it take him so long?  He's angry with this statement by Dr. Hannah Rosenblum, M.D., at the CDC.  See it below.  From the Borinquagato report, titled, "All-Cause Mortality Effects of COVID.  

COVID-19 vaccine safety monitoring is the most robust in U.S. history and the two complementary surveillance systems used in this study should bolster confidence that mRNA COVID-19 vaccines are safe,” said co-author Hannah Rosenblum, MD, also of the CDC, in a statement.  

In my day, we used to call these people bobbleheads, critters whose heads would bobble uncontrollably and incessantly.  And as I read this, all I could do is think of other mouths somewhere deep inside the alphabet agency soup.  It's a moral challenge to call these doctors and M.D.s bobbleheads, for what professional would allow himself or herself to be reduced to being a yesman just so that they can run cover for the deadliest vaccines in world history?  What would make them become this?  Money?  Blackmail?  We know, or at least we're learning what an unmitigated disaster the medical-industrial complex is and has been ever since the Flexner Report.  

Dr. Mobeen is smart, there's no doubt about that.  None.  But once anyone begins to accept the different categories of vaccines as operational language in some mass health plan, they've lost me.  Health is too personal, way too personal. to be left up to some mass plan.  Never accept anything that is perceived or run on a mass scale.  Ever.  Ever.  

Here is Peter Marks, Director of the FDA, 

As with all vaccines for any population, when authorizing COVID-19 vaccines intended for pediatric age groups, the FDA ensures that our evaluation and analysis of the data is rigorous and thorough.  Peter Marks, M.D., Ph.D., Director of the FDA’s Center for Biologics Evaluation & Research, June 17, 2022. 

Here is Pfizer's representative, Dr. William Gruber, Pfizer’s VP of vaccine clinical R & D. 

Yeah, I’ll leave it to Moderna to describe how they address their vaccine dosage.  But I think . . . “Obviously, we don’t have a complete understanding of the nature of the way the vaccine works.” In producing an immune results.   You have to go by the results!  Do these remarks sound like anyone is in control of vaccine quality control AT ALL!!!!!!  I mean at all!!!!!!

DR. WILLIAM GRUBER, PFIZER'S VP OF VACCINE CLINICAL TRIALS: “Obviously, we don’t have a complete understanding of the nature of the way the vaccine works.”

A trailer of my latest interview of Dr David Wiseman who expertly provides a critical evaluation of the FDA's authorisation of both Pfizer & Moderna's 💉 for children as young as 6 months old 🔥💣 #Pfizer #mRNA #FDA
Premieres later today 👇 pic.twitter.com/OtSrTw5Zz9

— Sonia Elijah (@sonia_elijah) July 7, 2022

0:00  MEG TIRRELL [reporter based in New York for CNBC] Pfizer and Moderna getting Emergency Use Authorization, EUA, for their vaccines down to 6 months of age, but the youngest age group yet eligible, the only one yet so far has not had access to the vaccine, yet eligible for vaccination.  The only

“A with all vaccines for any population, when authorizing COVID-19 vaccines intended for pediatric age groups, the FDA ensures that our evaluation and analysis of the data is rigorous and thorough.”  Peter Marks, M.D., Ph.D., Director of the FDA’s Center for Biologics Evaluation & Research, June 17, 2022.

0:16  Sonia Elijah interviews Dr. David Wiseman on the FDA’s controversial decision to authorize Moderna & Pfizer-BioNTech’s COVID-19 vaccines for children as young as 6 months old, based on a unanimous vote by VRBPAC, the FDA’s expert advisory committee, during the June 14-15 virtual meeting. 

David Wiseman, thank you so much for talking with me again.

WISEMAN: . . . the FDA, so that the data on the third vaccine dose data is “imprecise, it’s unstable.”  We have no idea what the efficacy is for Pfizer in the third dose.  If you have no idea what the efficacy is, then you cannot begin to calculate a risk-benefit ratio.  FDA believes that the drug “may be effective” and that the benefits outweigh the risks.  If you don’t know what the benefits are, if you don’t know what the efficacy is, how can you calculate what the risk-benefit ratio is?

[Here is the full interview with David Wiseman.]

The Consumer Representative on the FDA Committee, Dr. Jay Portnoy,  asked probably the most important question I’ve seen asked in any of these vaccine meetings. 

1:15  I’m confused about the dosing in terms of micrograms, because

Dr. Jay Portnoy, M.D.

Consumer Rep on the FDA’s VRBPAC (Vaccine & Related Biological Products Advisory Committee)  He asked the most important question that I’d see anybody ask in these hearings.  You’re dosing is 3mcg.  Moderna’s dosing is 25 mcg.  Clearly, we’re thinking of micrograms the way that we would think of proteins, a way of inducing an immune response.  Purpose of mRNA is to induce protein production.  So is your mRNA more efficient at making cells produce protein, or how shall we think of micrograms “in terms of the amount of spike protein that’s produced by the cells?” Can you kind of clarify that? 

Dr. William Gruber, Pfizer’s VP of vaccine clinical R & D. 

1:50  Yeah, I’ll leave it to Moderna to describe how they address their vaccine dosage.  But I think . . . “Obviously, we don’t have a complete understanding of the nature of the way the vaccine works.” In producing an immune results.   You have to go by the results! 

“But have you ever measured the amount of protein that’s produced as a result of the mRNA?” And how many cells are producing in it and how persistent that production is for a given microgram of mRNA?

That’s a pretty broad question. 

A fundamental scientific question is avoided.

You might like this site, TrialSite News.  Headquartered in Utah, its Twitter label reads, "TrialSite News is the only digital-media dedicated 100% to transparent and open coverage of clinical research trial sites around the globe."